{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:05:43Z","timestamp":1783181143215,"version":"3.54.6"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Chronic kidney disease (CKD) presents a significant burden on global health, with cardiovascular disease (CVD) being a leading cause of mortality in this population. Despite advancements in pharmacotherapies, preventing CVD in CKD patients remains challenging due to the intricate interplay of traditional risk factors and novel pathophysiological processes. This review aims to elucidate the current understanding of CVD prevention in CKD, encompassing epidemiology, risk factors, diagnostic considerations, and pharmacological therapeutic strategies. CKD patients exhibit a unique cardiovascular risk profile characterized by traditional risk factors such as hypertension and dyslipidemia, as well as CKD-specific factors including albuminuria, vascular calcification, and valvulopathies. The utility of coronary artery calcium scoring in risk stratification and the efficacy of aspirin, lipid-lowering agents, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists in CVD prevention are discussed. Despite promising findings, challenges such as lack of specific guidelines and data gaps persist, highlighting the need for multidisciplinary efforts to address the CVD burden in the CKD population effectively. Further research is warranted to optimize preventative strategies and improve outcomes in this high-risk population.<\/jats:p>","DOI":"10.1097\/crd.0000000000000746","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T14:00:32Z","timestamp":1733320832000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular Disease in Patients with Chronic Kidney Disease: Current Understanding, Preventative Strategies, and Future Directions"],"prefix":"10.1097","author":[{"given":"Robert","family":"Naami","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Disease, Case Western Reserve University School of Medicine, Cleveland, OH"},{"name":"Department of Cardiovascular Disease, University Hospitals Cleveland Medical Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew M.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Case Western Reserve University School of Medicine, Cleveland, OH"},{"name":"Department of Cardiovascular Disease, University Hospitals Cleveland Medical Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Datla","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Case Western Reserve University School of Medicine, Cleveland, OH"},{"name":"Department of Cardiovascular Disease, University Hospitals Cleveland Medical Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Case Western Reserve University School of Medicine, Cleveland, OH"},{"name":"Department of Cardiovascular Disease, University Hospitals Cleveland Medical Center, Cleveland, OH"},{"name":"Department of Cardiovascular Disease, Division of Nephrology and Hypertension, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadeer","family":"Al-Kindi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Case Western Reserve University School of Medicine, Cleveland, OH"},{"name":"Department of Cardiovascular Disease, University Hospitals Cleveland Medical Center, Cleveland, OH"},{"name":"Department of Cardiovascular Disease, Harrington Heart and Vascular Institute, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Neeland","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Case Western Reserve University School of Medicine, Cleveland, OH"},{"name":"Department of Cardiovascular Disease, University Hospitals Cleveland Medical Center, Cleveland, OH"},{"name":"Department of Cardiovascular Disease, Harrington Heart and Vascular Institute, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"R1-20241204","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019.","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"R2-20241204","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","article-title":"The global burden of cardiovascular diseases and risk factors: 2020 and beyond.","volume":"74","author":"Mensah","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R3-20241204","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCRESAHA.116.309115","article-title":"Decline in cardiovascular mortality.","volume":"120","author":"Mensah","year":"2017","journal-title":"Circ Res"},{"key":"R4-20241204","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022.","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"R5-20241204","article-title":"Centers for Disease Control and Prevention Chronic Kidney Disease 2015."},{"key":"R6-20241204","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review.","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"R7-20241204","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-20241204","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4103\/1319-2442.164607","article-title":"A cross-sectional study of dialysis practice-patterns in patients with chronic kidney disease on maintenance hemodialysis.","volume":"26","author":"Kulkarni","year":"2015","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R9-20241204","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"R10-20241204","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","article-title":"Cardiovascular disease risk among cancer survivors: the Atherosclerosis Risk In Communities (ARIC) Study.","volume":"80","author":"Florido","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R11-20241204","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2020.07.011","article-title":"Novel risk factors for progression of diabetic and nondiabetic CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.","volume":"77","author":"Anderson","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"R12-20241204","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.112.123992","article-title":"Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease.","volume":"127","author":"Bansal","year":"2013","journal-title":"Circulation"},{"key":"R13-20241204","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review.","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R14-20241204","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","article-title":"Hypertension in CKD: core curriculum 2019.","volume":"74","author":"Ku","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R15-20241204","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.hfc.2008.03.008","article-title":"Epidemiology of chronic kidney disease in heart failure.","volume":"4","author":"Ahmed","year":"2008","journal-title":"Heart Fail Clin"},{"key":"R16-20241204","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Conference participants. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review.","volume":"74","author":"Sarnak","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R17-20241204","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fcell.2019.00314","article-title":"Unraveling cardiovascular risk in renal patients: a new take on old tale.","volume":"7","author":"Provenzano","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"R18-20241204","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome.","volume":"52","author":"Ronco","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl B","key":"R19-20241204","doi-asserted-by":"crossref","first-page":"22B","DOI":"10.1016\/S0828-282X(08)71026-2","article-title":"Chronic kidney disease, heart failure and anemia.","volume":"24","author":"Virani","year":"2008","journal-title":"Can J Cardiol"},{"key":"R20-20241204","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"R21-20241204","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure: current concepts and emerging therapies.","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"R22-20241204","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options.","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"R23-20241204","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"R24-20241204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.ajkd.2012.06.017","article-title":"Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study.","volume":"60","author":"Smink","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R25-20241204","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/sj.ki.5000284","article-title":"The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population.","volume":"69","author":"Irie","year":"2006","journal-title":"Kidney Int"},{"key":"R26-20241204","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ajh\/hpu225","article-title":"Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification.","volume":"28","author":"Agharazii","year":"2015","journal-title":"Am J Hypertens"},{"key":"R27-20241204","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/toxins10050202","article-title":"Role of uremic toxins for kidney, cardiovascular, and bone dysfunction.","volume":"10","author":"Fujii","year":"2018","journal-title":"Toxins (Basel)"},{"key":"R28-20241204","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R29-20241204","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ndt\/gfv398","article-title":"Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure.","volume":"31","author":"Andersen","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"R30-20241204","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.","volume":"305","author":"Palmer","year":"2011","journal-title":"JAMA"},{"key":"R31-20241204","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/cells11030509","article-title":"Decreased concentration of fibroblast growth factor 23 (FGF-23) as a result of supplementation with selenium and coenzyme q10in an elderly Swedish population: a sub-analysis.","volume":"11","author":"Alehagen","year":"2022","journal-title":"Cells"},{"key":"R32-20241204","doi-asserted-by":"crossref","first-page":"e02","DOI":"10.15420\/ecr.2021.25","article-title":"Valvular heart disease in patients with chronic kidney disease.","volume":"17","author":"Kipourou","year":"2022","journal-title":"Eur Cardiol"},{"key":"R33-20241204","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12872-018-0747-y","article-title":"Cardiac valve calcification and risk of cardiovascular or all-cause mortality in dialysis patients: a meta-analysis.","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"R34-20241204","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ki.2009.298","article-title":"Incidence and progression of coronary calcification in chronic kidney disease: the multi-ethnic study of atherosclerosis.","volume":"76","author":"Kestenbaum","year":"2009","journal-title":"Kidney Int"},{"key":"R35-20241204","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2011.04.024","article-title":"Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) study.","volume":"58","author":"Budoff","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R36-20241204","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/0886022X.2019.1595646","article-title":"Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis.","volume":"41","author":"Wang","year":"2019","journal-title":"Ren Fail"},{"key":"R37-20241204","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamacardio.2017.0363","article-title":"Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease.","volume":"2","author":"Chen","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R38-20241204","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2011.69","article-title":"Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis.","volume":"80","author":"Russo","year":"2011","journal-title":"Kidney Int"},{"key":"R39-20241204","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000294405","article-title":"Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients.","volume":"31","author":"Shantouf","year":"2010","journal-title":"Am J Nephrol"},{"key":"R40-20241204","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jacc.2010.02.068","article-title":"Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.","volume":"56","author":"Jardine","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R41-20241204","first-page":"341","article-title":"Aspirin use in chronic kidney disease: is cardiovascular risk reduction worth the risk?","volume":"13","author":"Kramer","year":"2021","journal-title":"J Interv Cardiol"},{"key":"R42-20241204","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","article-title":"Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study).","volume":"32","author":"Goicoechea","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"R43-20241204","first-page":"CD008834","article-title":"Antiplatelet agents for chronic kidney disease.","author":"Palmer","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R44-20241204","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly.","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"R45-20241204","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.ajkd.2016.01.019","article-title":"Aspirin use and incident cardiovascular disease, kidney failure, and death in stable kidney transplant recipients: a post hoc analysis of the folic acid for vascular outcome reduction in transplantation (FAVORIT) trial.","volume":"68","author":"Dad","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R46-20241204","doi-asserted-by":"crossref","first-page":"162","DOI":"10.12997\/jla.2019.8.2.162","article-title":"Aspirin for primary prevention of cardiovascular disease.","volume":"8","author":"Kim","year":"2019","journal-title":"J Lipid Atheroscler"},{"key":"R47-20241204","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease.","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"R48-20241204","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ekir.2019.03.016","article-title":"Cardiovascular event rates among hemodialysis patients across geographical regions-a snapshot from the dialysis outcomes and practice patterns study (DOPPS).","volume":"4","author":"Stirnadel-Farrant","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R49-20241204","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"R50-20241204","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"R51-20241204","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"R52-20241204","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"R53-20241204","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000080241","article-title":"Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.","volume":"27","author":"Wanner","year":"2004","journal-title":"Kidney Blood Press Res"},{"key":"R54-20241204","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"R55-20241204","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"R56-20241204","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R57-20241204","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R58-20241204","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40620-020-00707-2","article-title":"Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology.","volume":"33","author":"Pontremoli","year":"2020","journal-title":"J Nephrol"},{"key":"R59-20241204","doi-asserted-by":"crossref","first-page":"136","DOI":"10.23876\/j.krcp.22.001","article-title":"GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions.","volume":"41","author":"Yu","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"R60-20241204","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials.","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R61-20241204","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R62-20241204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12933-020-01197-z","article-title":"Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.","volume":"20","author":"Yamada","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"R63-20241204","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/phar.2737","article-title":"Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis.","volume":"42","author":"Kelly","year":"2022","journal-title":"Pharmacotherapy"},{"key":"R64-20241204","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomized trial.","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R65-20241204","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R66-20241204","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R67-20241204","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"R68-20241204","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R69-20241204","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R70-20241204","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"R71-20241204","article-title":"Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis.","volume":"8","author":"Li","year":"2021","journal-title":"Front Med"},{"key":"R72-20241204","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R73-20241204","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R74-20241204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"R75-20241204","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial.","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"R76-20241204","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study).","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"R77-20241204","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"R78-20241204","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes.","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"R79-20241204","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease.","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"R80-20241204","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.","volume":"102","year":"2022","journal-title":"Kidney Int"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T14:00:55Z","timestamp":1733320855000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":80,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000746","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]}}}